MEGGLE, a German family business established in 1887, carries on the tradition of focusing on quality and serving customers, and continues to develop the lactose series products needed by the pharmaceutical industry by combing with own resource superiority. It has supplied 26 kinds of lactose and lactose-containing co-processed excipients to over 100 regions in the world, with the dosage forms from traditional solid preparation to dry powder inhalation, etc., and the entire series of lactose that meets various process needs from wet granulation to direct compression, etc.
MEGGLE has become a world-leading lactose producer and supplier upon stable and reliable quality, and rapid and effective services, and cooperated with numerous international famous pharmaceutical enterprises, with the service network all over more than 100 countries and regions, and a high reputation in the industry. MEGGLE has a perfect quality management system: it obtained the EXCiPACT certificate issued by SGS in 2014, and has again passed the review and renewed the certificate in 2017. To obtain the certificate, enterprises shall be strictly investigated the GMP/GDP design and execution according to IPEC-PQG GMP Guide, and obtaining the certificate proves an enterprise’s attention to and strength in quality management.
Based on the stable supply consideration, MEGGLE now has two production sites separately in Germany and the U.S. that comply with the same quality management requirements. MEGGLE has two giant spray drying towers with height above 20m where the FlowLac series products popular with the broad pharmaceutical enterprises and MEGGLE’s numerous co-processed excipients are produced, to guarantee the intra-batch stability and inter-batch stability of performance indicators of products.
Since the birth of the world’s first lactose Tablettose that directly meets direct compression process requirements, MEGGLE has been committed to the R&D and production of the excipients for direct compression to simplify production steps, increase productivity, reduce production cost, and improve product quality: among its products, there is not only the lactose anhydrous DuraLac that can be directly used for dry granulation and direct compression and the spherical lactose monohydrate FlowLac series with good flow and compressibility, but also the Cellactose and MicroceLac series products with excellent flow, blending property and compressibility that are obtained through co-processing cellulose, microcrystalline cellulose, and lactose with special process. MEGGLE also has managed to co-process lactose and starch to obtain StarLac, and has recently successfully launched the CombiLac (lactose+starch+MCC) for direct compression that is co-processed with three common excipients.
Even the common milled and sieved lactose shall also be divided into different varieties according to the micromeritics requirements at the time of application, to separately meet the requirements of granulation for excipients of different particle sizes, and the needs of different processes such as capsule filling and powder preparation, etc.
In addition, MEGGLE is also an important supplier of lactose for global dry powder inhalation preparations and capable of furnishing customers with sieved, milled, and micronized series standard products, and has the capacity to customize products for customers. Its advanced production technology and dedicated production line can ensure the consistent high quality, while its experienced technical service team can help customers faster find the ideal specifications.
MEGGLE established a representative office in Shanghai, China in 2003, and set up an applied technology laboratory in Zhangjiang Pharma Valley th...
(All Rights Reserved)